Episurf Medical reaches milestone of 500 implants
Episurf Medical (NASDAQ: EPIS B) today announces that the company has reached another milestone by the planning of the 500th surgery with the Episealer® implant in the coming weeks. The 500th Episealer® implant was ordered by a clinic in Germany in the state of Thuringia.
“Episurf Medical has reached a milestone. Slowly but surely the good and long-lasting clinical results are gaining momentum in the treatment of early and focal cartilage lesions in the knee joint. It is all very reassuring" says Prof. Leif Ryd, Senior Medical Advisor to Episurf Medical.
“Reaching this milestone while we are experiencing a continuous flow of successful patient outcomes is of great importance to us. Our customers are constantly talking to us about the challenge in treating the middle-aged patients who suffer from early cartilage and bone lesions in the knee joint. It is our vision to help these patients to return to a normal lifestyle, and we are very determined on delivering on this vision” says Pål Ryfors, CEO Episurf Medical.
For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel:+46 (0) 709 62 36 69
About Episurf Medical
Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and personalised treatment alternatives. Episurf Medical’s Episealer® personalised implants and Epiguide® surgical drill guides are developed for treating localized cartilage injury in joints. Episurf Medical’s μiFidelity® system enables implants to be cost-efficiently tailored to each individual’s unique injury for the optimal fit and minimal intervention. Episurf Medical’s head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company’s website: www.episurf.com.
This information is information that Episurf Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.45 CET on 20 February 2019.